NeuroPace, Inc. (NPCE)
NASDAQ: NPCE · Real-Time Price · USD
11.53
+0.39 (3.50%)
Dec 20, 2024, 4:00 PM EST - Market closed

Company Description

NeuroPace, Inc. operates as a medical device company in the United States.

The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy.

It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.

The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures.

NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

NeuroPace, Inc.
NeuroPace logo
Country United States
Founded 1997
IPO Date Apr 22, 2021
Industry Medical Devices
Sector Healthcare
Employees 171
CEO Joel Becker

Contact Details

Address:
455 North Bernardo Avenue
Mountain View, California 94043
United States
Phone 650 237 2700
Website neuropace.com

Stock Details

Ticker Symbol NPCE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001528287
CUSIP Number 641288105
ISIN Number US6412881053
Employer ID 22-3550230
SIC Code 3841

Key Executives

Name Position
Joel D. Becker Chief Executive Officer, President and Director
Rebecca L. Kuhn Chief Financial Officer, Vice President of Finance and Administration
Dr. Martha J. Morrell M.D. Chief Medical Officer
Dylan St. John Chief of Operations and Development
Leah Akin General Counsel and Corporate Secretary
Kelley Nicholas Vice President of Sales
Amy Treadwell Vice President of Human Resources

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Nov 4, 2024 SCHEDULE 13G Filing
Oct 28, 2024 144 Filing
Oct 3, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 3, 2024 144 Filing
Aug 13, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report